Vor Price To Operating Cash Flows Ratio from 2010 to 2025

VOR Stock  USD 0.75  0.02  2.60%   
Vor Biopharma Price To Operating Cash Flows Ratio yearly trend continues to be relatively stable with very little volatility. Price To Operating Cash Flows Ratio is likely to drop to -0.8. During the period from 2010 to 2025, Vor Biopharma Price To Operating Cash Flows Ratio destribution of quarterly values had range of 140 from its regression line and mean deviation of  36.31. View All Fundamentals
 
Price To Operating Cash Flows Ratio  
First Reported
2010-12-31
Previous Quarter
(0.77)
Current Value
(0.80)
Quarterly Volatility
42.42132762
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vor Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vor Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.5 M, Interest Income of 4.5 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Vor financial statements analysis is a perfect complement when working with Vor Biopharma Valuation or Volatility modules.
  
Check out the analysis of Vor Biopharma Correlation against competitors.
To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

Latest Vor Biopharma's Price To Operating Cash Flows Ratio Growth Pattern

Below is the plot of the Price To Operating Cash Flows Ratio of Vor Biopharma over the last few years. It is Vor Biopharma's Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vor Biopharma's overall financial position and show how it may be relating to other accounts over time.
Price To Operating Cash Flows Ratio10 Years Trend
Slightly volatile
   Price To Operating Cash Flows Ratio   
       Timeline  

Vor Price To Operating Cash Flows Ratio Regression Statistics

Arithmetic Mean(56.87)
Geometric Mean24.06
Coefficient Of Variation(74.59)
Mean Deviation36.31
Median(79.77)
Standard Deviation42.42
Sample Variance1,800
Range140
R-Value0.71
Mean Square Error957.05
R-Squared0.50
Significance0
Slope6.32
Total Sum of Squares26,994

Vor Price To Operating Cash Flows Ratio History

2025 -0.8
2024 -0.77
2023 -1.51
2022 -3.09
2021 -6.25
2020 -38.36
2019 -141.25

About Vor Biopharma Financial Statements

Vor Biopharma shareholders use historical fundamental indicators, such as Price To Operating Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Although Vor Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Vor Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vor Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Price To Operating Cash Flows Ratio(0.77)(0.80)

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.